NCT00859807View on ClinicalTrials.gov

A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Falciparum Malaria
Interventions
DRUG

Flavoquine®, Camoquin® Suspension

Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.

DRUG

Flavoquine®, Camoquin® Suspension

Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.

Trial Locations (1)

400709

Pfizer Investigational Site, Navi Mumbai

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00859807 - A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects | Biotech Hunter | Biotech Hunter